

February 22<sup>nd</sup>-23<sup>rd</sup>-24<sup>th</sup>, 2022 3.00 - 6.00 p.m. (CET) 3<sup>rd</sup> International Scientific School







**DIGITAL EDITION** 

Novel Psychoactive Substances (NPS) are a broad variety of drugs not regulated by present legislation. The advent of NPS has contributed to the appearance and growth of a new 'drug scenario' characterized by an increased number of drug users among youth and the consumption of drugs with unknown effects or safety profiles. Preclinical and clinical findings have shown that at lower doses NPS may produce effects comparable to those of illicit psychoactive drugs, such as Cannabis, heroin, cocaine and MDMA, however, with more severe consequences.

The first wave of NPS came to Europe in the early 2000s in the form of synthetic cannabinoids followed by synthetic cathinones and phenethylamines. From 2016, a rise in the availability of novel synthetic opioids (NSO) was registered in Europe. NSO are the most dangerous NPS since they mimic morphine and heroin and are many times more potent than these opioids in producing acute toxicity. Based on their increasing prevalence, it has been estimated that their use is likely to become the primary source of NPS-associated deaths in Europe.

This International Course intends to provide undergraduate and PhD students, but also health care professionals, with a unique opportunity to gain expertise in the field of NPS and NSO by an up-to-date overview of their pharmacology, structure-activity relationships, and toxicology, and the detrimental effects associated with their intake, the overall aim being that of preventing health damage.

The course is funded by the Fondazione di Sardegna and organized by Prof. Maria Antonietta De Luca of the Department of Biomedical Sciences (DiSB-UniCa).

## Chair

Maria Antonietta De Luca, PhD University of Cagliari I Italy

## **Scientific Advisory Board**

Gaetano Di Chiara, MD University of Cagliari, CNR I Italy

Fabrizio Schifano, MD, FRCPsych Psychopharmacology, Drug Misuse and NPS Research Unit, University of Hertfordshire I UK

Michael Baumann, PhD
Designer Drug Research Unit (DDRU), NIDA, NIH I USA

## REGISTRATION AT: infonuovedroghe@gmail.com

Please send a brief CV with affiliation

For further informations: www.sites.unica.it/issnps/ facebook.com/infonuovedroghe

## **Faculty**

Emilio Ambrosio, PhD

National University for Distance Learning (UNED) I Spain

Michael Baumann, PhD

Designer Drug Research Unit (DDRU), NIDA, NIH I USA

Valeria Catalani

University of Hertfordshire I UK

Maria Antonietta De Luca, PhD University of Cagliari I Italy

Gaetano Di Chiara, MD University of Cagliari, CNR I Italy

Michael Evans-Brown

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) | Portugal

Magin Farré, MD, PhD

Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona I Spain

Raffaele Giorgetti, MD, PhD Università Politecnica delle Marche I Italy

Antonis Goulas, MD, PhD Aristotle University of Thessaloniki I Greece Amira Guirguis, PhD, MPharm Swansea University I UK

Alejandro Higuera Matas, PhD National University for Distance Learning (UNED) | Spain

Åse Marit Leere Øiestad, PhD
Oslo University Hospital | Norway

Matteo Marti, PhD University of Ferrara | Italy

Norbert Scherbaum, MD

LVR-Hospital Essen, University Duisburg-Essen I Germany

Fabrizio Schifano, MD, FRCPsych Drug Misuse and NPS Research Unit | University of Hertfordshire | UK

Marta Torrens, MD, PhD

IMIM-Hospital del Mar, Universitat Autònoma Barcelona and Universitat de Vic - Universitat Central de Catalunya I Spain

Marthe Vandeputte Ghent University | Belgium

Aviv M. Weinstein, PhD Ariel University I Israel





